Slow Capital Inc. Increases Holdings in Moderna, Inc. (NASDAQ:MRNA)

Slow Capital Inc. grew its holdings in Moderna, Inc. (NASDAQ:MRNA) by 18.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 24,365 shares of the company’s stock after purchasing an additional 3,816 shares during the period. Slow Capital Inc.’s holdings in Moderna were worth $2,423,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new stake in shares of Moderna in the fourth quarter worth $628,359,000. Renaissance Technologies LLC grew its holdings in Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock valued at $657,720,000 after purchasing an additional 1,984,458 shares during the period. The Manufacturers Life Insurance Company grew its holdings in Moderna by 77.3% during the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock valued at $400,367,000 after purchasing an additional 1,690,341 shares during the period. Morgan Stanley grew its holdings in Moderna by 19.1% during the fourth quarter. Morgan Stanley now owns 4,187,353 shares of the company’s stock valued at $752,133,000 after purchasing an additional 670,284 shares during the period. Finally, Invesco Ltd. grew its holdings in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after purchasing an additional 517,683 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Trading Down 0.3 %

NASDAQ MRNA traded down $0.28 during trading hours on Wednesday, hitting $103.51. 790,879 shares of the company were exchanged, compared to its average volume of 4,196,207. The stock has a 50-day moving average price of $100.10 and a 200 day moving average price of $93.52. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.93. The stock has a market cap of $39.63 billion, a PE ratio of -8.36 and a beta of 1.62.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion for the quarter, compared to analysts’ expectations of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The firm’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.61 earnings per share. Analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a report on Thursday, April 11th. William Blair restated a “market perform” rating on shares of Moderna in a research report on Monday, April 1st. Royal Bank of Canada restated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research report on Thursday, March 28th. Canaccord Genuity Group boosted their price objective on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Finally, Jefferies Financial Group restated a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $126.49.

Insider Activity

In other news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the transaction, the director now owns 2,101,931 shares of the company’s stock, valued at $229,236,594.86. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the completion of the sale, the director now owns 2,101,931 shares in the company, valued at $229,236,594.86. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO James M. Mock sold 705 shares of the company’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 79,954 shares of company stock valued at $8,407,976. 15.20% of the stock is currently owned by insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.